| Amy Welsh |
Amy Welsh is currently the Chief Commercial Officer at Agile Therapeutics, Inc. She previously worked as the Vice President-Marketing at Antares Pharma, Inc. from 2017 to 2020. Ms. Welsh completed her undergraduate degree at LaSalle University. |
| Scott M. Coiante |
Scott M. Coiante is currently the Chief Financial Officer, CAO & Senior VP at Agile Therapeutics, Inc. He previously worked as the Treasurer, Chief Accounting Officer & VP-Finance at Medarex, Inc. from 2002 to 2010. Prior to that, he was the Head-Financial Reporting at Ernst & Young LLP from 1989 to 2000. From 2010 to 2019, he held the position of CFO, Principal Accounting Officer & Senior VP at Agile Therapeutics, Inc. He also served as a Member of the New Jersey Technology Council. From 2019 to 2023, he was the Chief Financial Officer & Senior Vice President at Aprea Therapeutics AB and Aprea Therapeutics, Inc. He also held the position of Secretary at Aprea Therapeutics, Inc. Mr. Coiante completed his undergraduate degree at Villanova University. |
| Paul Korner |
Paul Korner is currently the Director at Versameb AG, Independent Director at Voltron Therapeutics, Inc., Chief Medical Officer at Agile Therapeutics, Inc., and Principal at Laidlaw Venture Partners. Previously, he held positions such as Executive Director-Medical Affairs at Berlex Laboratories, Inc., VP-Medical Strategy & Clinical Development at Sarepta Therapeutics, Inc., Vice President-Medical Affairs at Ferring Pharmaceuticals, Inc., VP-Medical Affairs & Women's Healthcare at Bayer HealthCare Pharmaceuticals, Inc., Chief Medical Officer & Executive Vice President at Ardelyx, Inc., President at Ferring International Pharmascience Center US, Inc., and Senior VP-Clinical Development & Medical Affairs at Sio Gene Therapies, Inc. Dr. Korner obtained a doctorate degree from Loyola University New Orleans and Stritch School of Medicine, an undergraduate degree from the University of Illinois, and an MBA from Coles College of Business. |
| Robert G. Conway |
Robert G. Conway is the founder. He founded R.G. Conway & Associates, Inc. in 1997, where he held the title of Principal from 1997 to 2019. Currently, Mr. Conway is the Chief Supply Chain & Corporate Planning Officer at Agile Therapeutics, Inc. since 2004. Mr. Conway previously worked at Johnson & Johnson as a Principal. He obtained his undergraduate degree from New Jersey Institute of Technology. |
| Alfred F. Altomari |
Alfred F. Altomari is currently the Chairman & Chief Executive Officer at Agile Therapeutics, Inc. since 2016. He is also an Independent Director at Insmed, Inc. since 2012 and a Director at Trenton Area Soup Kitchen since 2015. Additionally, he serves as a Trustee at Drexel University. In his former positions, Mr. Altomari served as the Chief Executive Officer & Director at Barrier Therapeutics, Inc. from 2008 to 2011. He was also the Chairman at NB Therapeutics from 2010 to 2013 and Baudax Bio, Inc. from 2019 to 2022. Furthermore, he held director roles at DUSA Pharmaceuticals, Inc., Signum Biosciences, Inc., Auxilium Pharmaceuticals LLC, Societal CDMO, Inc., and Nitric Bio, Inc. He also served as a Trustee at BioNJ, Inc.Mr. Altomari obtained his undergraduate degree from Drexel University in 1982 and an MBA from Rider University in 1986. |
| Geoffrey P. Gilmore |
Geoffrey P. Gilmore's career history includes current and former positions as well as his education. Currently, he is the Chief Administrative Officer at Agile Therapeutics, Inc. He started this position in 2022. Previously, he worked at Bristol Myers Squibb Co. from 1997 to 2008, where he held the title of Vice President & Senior Counsel-Law Department from 2003 to 2008. From 2008 to 2012, he worked at Amicus Therapeutics, Inc. as the Secretary, Senior Vice President & General Counsel. In 2002, he worked as a Senior Attorney at Wyeth Pharmaceuticals LLC. He also worked as an Associate at Ballard Spahr LLP and Montgomery McCracken Walker & Rhoads LLP. From 2012 to 2016, he was a Principal at LifeSci Advisors LLC. In terms of education, he completed his undergraduate degree at Franklin & Marshall College and his graduate degree at The University of Michigan Law School. |
| Sharon Barbari |
Sharon Barbari is an Independent Director at Agile Therapeutics, Inc. and VYNE Therapeutics, Inc. She previously served as an Independent Director at Sonoma Pharmaceuticals, Inc. from 2014 to 2021. She also held positions as a Director at VYNE Pharmaceuticals Ltd., Menlo Therapeutics, Inc., and Phytogen Life Sciences. Additionally, she was a Director at The Association of Bioscience Financial Officers from 2007 to 2021. Ms. Barbari has a background in finance and served as the Chief Financial Officer at Gilead Sciences, Inc. from 1998 to 2002. She also held the position of CFO, Senior VP-Finance & Administration at InterMune, Inc. from 2002 to 2004, and Chief Financial Officer, Secretary & Executive VP at Cytokinetics, Inc. from 2004 to 2017. Prior to her roles in the biotech industry, she was Vice President-Strategic Planning at Foote, Cone & Belding Healthcare. Ms. Barbari obtained her undergraduate degree from San Jose State University. |
| Josephine Torrente |
Josephine Torrente is an Independent Director at Agile Therapeutics, Inc. and a Director at Hyman, Phelps & McNamara PC. She previously worked as an Executive VP-Corporate & Regulatory Affairs at Sprout Pharmaceuticals, Inc. Ms. Torrente has an undergraduate degree from Case Western Reserve University, a graduate degree from The University of Alabama at Birmingham, and a graduate degree from Temple University Beasley School of Law. |
| Sandra A. Carson |
Sandra A. Carson is currently an Independent Director at Agile Therapeutics, Inc. She is also a Director of Reproductive Endocrinology & Infertility at both Yale University and Women & Infants Corp. Previously, she served as the Director of Reproductive Endocrinology & Professor at Brown University from 2007 to 2013. From 2013 to 2019, she was the Vice President of Education at the American College of Obstetricians & Gynecologists. Dr. Carson has also held positions as the President of the American Society for Reproductive Medicine, Head of Reproductive Endocrinology at the American Board of Obstetrics & Gynecology, Inc., and Council Member at the National Institute of Child Health & Human Development. She obtained her doctorate degree from Northwestern University. |
| Seth H. Z. Fischer |
Seth H. Z. Fischer is currently serving as an Independent Director at Marinus Pharmaceuticals, Inc., Lead Independent Director at Agile Therapeutics, Inc., Independent Director at Esperion Therapeutics, Inc., and Independent Non-Executive Director at Milestone Pharmaceuticals, Inc. He is also an Advisor at Healthquest Capital Management Co LLC. In his former positions, Mr. Fischer served as the Chief Executive Officer & Director at VIVUS, Inc. from 2013 to 2017. He was the Group Chairman at Biosense Webster, Inc. from 2008 to 2012 and at North American Pharmaceuticals Co. from 2004 to 2007. He also held the position of Chairman-Worldwide Franchise at Cordis Corp. from 2008 to 2012. Additionally, he served as Group Chairman at Johnson & Johnson from 1983 to 2012 and as Chairman & President at Ortho-McNeil Pharmaceutical LLC from 2000 to 2004. Mr. Fischer was a Director at BioSig Technologies, Inc. from 2013 to 2019 and at Trius Therapeutics, Inc. in 2013. He also served as a Director at Spectrum Pharmaceuticals, Inc. from 2020 to 2023. Mr. Fischer obtained his undergraduate degree from The Ohio University in 1977. |
| John W. Hubbard |
John W. Hubbard is currently the Vice Chairman at the Children's Brain Tumor Foundation. He is also the Chairman at Precision Medicine Group LLC, Signant Health, and Agile Therapeutics, Inc. Additionally, he holds positions as a Director at Science 37, Inc., Advarra, Inc., and Genstar Capital Management LLC. He is a Member of the Drug Information Association and The American Society for Clinical Pharmacology & Therapeutics. In his former roles, Dr. Hubbard served as the President, Chief Executive Officer & Director at BioClinica, Inc. He was also the Chairman of the Association of Clinical Research Organizations. He served as a Director at Lifesci Acquisition II Corp., Science 37 Holdings, Inc., Life Sciences Pennsylvania, Transcelerate Biopharma, Inc., Pfizer Inc., and ICON Clinical Research, Inc. At ICON plc, he held the position of Group President-Global Clinical Research Services. Dr. Hubbard received his undergraduate degree from Santa Clara University and his doctorate from the University of Tennessee. |
